CBN (cannabinol): legal status and the state of research in France

Cannabinol was among the very first cannabinoids isolated by chemists, in the late nineteenth century. It was then thought to be responsible for the psychoactive effects of cannabis, until THC was identified in the middle of the twentieth century. CBN is today considered non-intoxicating, or only very weakly active at common doses. A fresh flower contains very little of it; an aged sample, or one exposed to the air, accumulates it gradually as its THC degrades.

CBN occupies a particular legal zone. Unlike HHC, H4CBD and THCP - classified as narcotics by the ANSM orders of June 2023 and June 2024 - it appears on no list of banned substances. Nor is it explicitly authorised. In practice, the majority of CBN products sold in France are hemp extracts subject to the same tolerance as CBD: compliant if the THC in the finished product stays at or below 0.30%. But as a new ingested ingredient, CBN would fall under the European Novel Food regulation, which would subject it to the same restrictions as ingested CBD since May 2026 - a point detailed in our article on the withdrawal of CBD gummies. That is why CBN is still mainly sold in oils for external use or as an incidental component of full-spectrum oils, and more rarely in ingested products.

CBN is sometimes presented in the trade press as "the sleep cannabinoid". That reputation rests on limited scientific grounds. Published studies remain few in number, often with small samples, and do not always separate the effect of CBN alone from that of other cannabinoids or of any melatonin combined with it. A 2023 review of the literature concluded that the evidence for a sedative effect specific to CBN remains insufficient to settle the question. Neither Inserm nor the HAS mentions CBN in their resources or recommendations on sleep. For a fuller picture of the most recent clinical data, our practical guide to CBN and sleep sets out a randomised trial published in 2024.

As with CBD, the use of CBN is not recommended for pregnant or breastfeeding women, for minors, for people on medical treatment (notably hypnotics, anxiolytics and anticoagulants) or for people with liver conditions. CBN is metabolised by cytochrome P450 enzymes, which can interfere with the breakdown of many medicines. Drowsiness is the effect most often reported by regular users: do not drive after taking it.

CBN alone is not what saliva tests look for, since they screen for THC. But full-spectrum hemp extracts contain traces of THC by construction. On 21 June 2023 the Cour de cassation confirmed that the commercial legality of a product does not exempt the driver in the event of a positive test.

Is CBN classified as a narcotic in France?

No. CBN appears on no narcotics schedule, unlike HHC, H4CBD and THCP, which have been banned since 2023-2024.

Can CBN gummies be sold legally in France?

That is uncertain. As a new ingested ingredient, CBN potentially falls under the Novel Food regulation, which exposes this type of product to the same risk of withdrawal as CBD gummies since May 2026.

Is CBN more legal than THC?

Yes, unambiguously on that point: THC is a scheduled narcotic, whereas CBN is subject to no explicit ban, only to a regulatory grey area on the Novel Food side.

What does a brand risk if it claims CBN "treats insomnia"?

Reclassification as a medicine by presentation, within the meaning of article L.5111-1 of the Public Health Code, with the penalties attached to the illegal sale of a medicine.